P
Pernille Poulsen
Researcher at Novo Nordisk
Publications - 90
Citations - 8597
Pernille Poulsen is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Type 2 diabetes & Insulin resistance. The author has an hindex of 36, co-authored 82 publications receiving 8055 citations. Previous affiliations of Pernille Poulsen include Odense University Hospital & Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Epigenetic differences arise during the lifetime of monozygotic twins
Mario F. Fraga,Esteban Ballestar,Maria F. Paz,Santiago Ropero,Fernando Setien,Maria Luisa Ballestar,Damia Heine-Suñer,Juan C. Cigudosa,Miguel Urioste,Javier Benitez,Manuel Boix-Chornet,Abel Sánchez-Aguilera,Charlotte Ling,Emma Carlsson,Pernille Poulsen,Allan Vaag,Zarko Stephan,Tim D. Spector,Yue Zhong Wu,Christoph Plass,Manel Esteller +20 more
TL;DR: Older monozygous twins exhibited remarkable differences in their overall content and genomic distribution of 5-methylcytosine DNA and histone acetylation, affecting their gene-expression portrait, indicating how an appreciation of epigenetics is missing from the understanding of how different phenotypes can be originated from the same genotype.
Journal ArticleDOI
Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study.
TL;DR: It is proposed that genetic predisposition is important for the development of abnormal glucose tolerance, and the notion of a multifactorial aetiology of Type II diabetes per se is confirmed.
Journal ArticleDOI
Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs
TL;DR: The association between low birth weight and NIDDM in twins is at least partly independent of genotype and may be due to intrauterine malnutrition.
Journal ArticleDOI
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
Stephen C. L. Gough,Bruce W. Bode,Vincent Woo,Helena W. Rodbard,Sultan Linjawi,Pernille Poulsen,L.H. Damgaard,John B. Buse +7 more
TL;DR: IDegLira combines the clinical advantages of basal insulin and GLP-1 receptor agonist treatment, resulting in improved glycaemic control compared with its components given alone, and was generally well tolerated.
Journal ArticleDOI
Genetic versus environmental aetiology of the metabolic syndrome among male and female twins.
TL;DR: A core complex including hyperinsulinaemia, obesity, hypertriglyceridaemia and low HDL-cholesterol is proposed with only weak associations to glucose concentrations and blood pressure levels with the notion of a multifactorial aetiology of the components including genetic and non-genetic factors confirmed.